| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oncolytic Virotherapy | 28 | 2024 | 280 | 6.790 |
Why?
|
| Oncolytic Viruses | 23 | 2024 | 204 | 5.500 |
Why?
|
| Glioma | 31 | 2024 | 1963 | 4.190 |
Why?
|
| Brain Stem Neoplasms | 8 | 2023 | 108 | 2.680 |
Why?
|
| Adenoviridae | 21 | 2024 | 1459 | 2.420 |
Why?
|
| Brain Neoplasms | 30 | 2024 | 4849 | 2.040 |
Why?
|
| E2F1 Transcription Factor | 8 | 2016 | 206 | 1.540 |
Why?
|
| Tumor Microenvironment | 11 | 2024 | 2864 | 0.900 |
Why?
|
| Autophagy | 7 | 2016 | 927 | 0.840 |
Why?
|
| Glioblastoma | 11 | 2023 | 1797 | 0.730 |
Why?
|
| Adenoviridae Infections | 2 | 2019 | 125 | 0.700 |
Why?
|
| Neoplastic Stem Cells | 9 | 2017 | 1443 | 0.660 |
Why?
|
| Adenovirus E1A Proteins | 6 | 2016 | 163 | 0.580 |
Why?
|
| Capsid | 1 | 2016 | 103 | 0.540 |
Why?
|
| Oligopeptides | 5 | 2024 | 429 | 0.540 |
Why?
|
| Promoter Regions, Genetic | 5 | 2014 | 3101 | 0.500 |
Why?
|
| Mice | 35 | 2024 | 34495 | 0.470 |
Why?
|
| Dacarbazine | 3 | 2016 | 485 | 0.440 |
Why?
|
| Animals | 43 | 2024 | 59536 | 0.440 |
Why?
|
| Telomerase | 2 | 2006 | 525 | 0.430 |
Why?
|
| Cell Line, Tumor | 27 | 2022 | 14551 | 0.430 |
Why?
|
| Retinoblastoma Protein | 3 | 2010 | 335 | 0.430 |
Why?
|
| Neoplasms | 8 | 2024 | 15193 | 0.420 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2011 | 123 | 0.390 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2022 | 588 | 0.390 |
Why?
|
| Virus Replication | 8 | 2016 | 709 | 0.380 |
Why?
|
| Antigens, Neoplasm | 2 | 2024 | 1506 | 0.380 |
Why?
|
| Osteosarcoma | 4 | 2022 | 929 | 0.380 |
Why?
|
| Epigenomics | 1 | 2011 | 266 | 0.360 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2020 | 100 | 0.350 |
Why?
|
| Humans | 67 | 2024 | 261506 | 0.330 |
Why?
|
| Gene Silencing | 2 | 2011 | 837 | 0.330 |
Why?
|
| Receptor, TIE-2 | 4 | 2016 | 82 | 0.330 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2007 | 69 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2022 | 8873 | 0.310 |
Why?
|
| Mice, Nude | 12 | 2020 | 4307 | 0.310 |
Why?
|
| Infratentorial Neoplasms | 2 | 2018 | 45 | 0.300 |
Why?
|
| Child | 13 | 2023 | 29154 | 0.300 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 2 | 2024 | 59 | 0.290 |
Why?
|
| Pyrans | 2 | 2016 | 20 | 0.280 |
Why?
|
| DNA-Binding Proteins | 3 | 2018 | 4821 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2022 | 3821 | 0.280 |
Why?
|
| Ependymoma | 2 | 2018 | 242 | 0.260 |
Why?
|
| Genetic Linkage | 1 | 2005 | 512 | 0.240 |
Why?
|
| Disease Models, Animal | 7 | 2023 | 7222 | 0.240 |
Why?
|
| Sirolimus | 1 | 2008 | 814 | 0.230 |
Why?
|
| Herpesvirus 1, Human | 1 | 2023 | 113 | 0.220 |
Why?
|
| Infusions, Intralesional | 1 | 2022 | 9 | 0.220 |
Why?
|
| DNA Methylation | 2 | 2018 | 2669 | 0.220 |
Why?
|
| Kynurenine | 1 | 2022 | 71 | 0.210 |
Why?
|
| Genetic Vectors | 4 | 2019 | 1694 | 0.210 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2022 | 69 | 0.210 |
Why?
|
| Adenoviruses, Human | 3 | 2016 | 181 | 0.210 |
Why?
|
| Genetic Therapy | 3 | 2015 | 1616 | 0.200 |
Why?
|
| Autophagy-Related Protein 5 | 3 | 2012 | 46 | 0.200 |
Why?
|
| Flow Cytometry | 4 | 2023 | 3033 | 0.190 |
Why?
|
| Antibodies | 1 | 2023 | 838 | 0.190 |
Why?
|
| Rhabdoid Tumor | 1 | 2020 | 110 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 6 | 2020 | 5395 | 0.180 |
Why?
|
| Immunotherapy | 3 | 2022 | 3341 | 0.180 |
Why?
|
| Astrocytoma | 1 | 2022 | 321 | 0.180 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 264 | 0.180 |
Why?
|
| Brain | 4 | 2023 | 4113 | 0.170 |
Why?
|
| Teratoma | 1 | 2020 | 236 | 0.170 |
Why?
|
| Mesothelioma | 1 | 2024 | 544 | 0.170 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 1910 | 0.160 |
Why?
|
| Syk Kinase | 1 | 2018 | 56 | 0.160 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2012 | 534 | 0.160 |
Why?
|
| Synapses | 1 | 2022 | 509 | 0.160 |
Why?
|
| Fluorine Radioisotopes | 1 | 2018 | 133 | 0.160 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 2 | 2008 | 62 | 0.160 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2016 | 204 | 0.150 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2007 | 518 | 0.150 |
Why?
|
| Blotting, Western | 4 | 2011 | 3536 | 0.140 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2014 | 591 | 0.140 |
Why?
|
| Bone Neoplasms | 2 | 2022 | 2576 | 0.140 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2007 | 323 | 0.140 |
Why?
|
| Cell Self Renewal | 1 | 2016 | 62 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 502 | 0.140 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2007 | 187 | 0.140 |
Why?
|
| Parkinson Disease | 1 | 2022 | 708 | 0.130 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2010 | 703 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 10035 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2022 | 1026 | 0.130 |
Why?
|
| Biomarkers, Tumor | 6 | 2018 | 10331 | 0.130 |
Why?
|
| Blood-Brain Barrier | 1 | 2017 | 238 | 0.130 |
Why?
|
| MicroRNAs | 3 | 2014 | 2947 | 0.130 |
Why?
|
| Capsid Proteins | 1 | 2016 | 185 | 0.130 |
Why?
|
| Antigen Presentation | 1 | 2016 | 272 | 0.130 |
Why?
|
| Sarcoma | 1 | 2005 | 1725 | 0.130 |
Why?
|
| Immunoblotting | 2 | 2008 | 886 | 0.130 |
Why?
|
| Alternative Splicing | 1 | 2018 | 584 | 0.130 |
Why?
|
| Cellular Senescence | 2 | 2014 | 382 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 1586 | 0.130 |
Why?
|
| Stem Cells | 1 | 2021 | 1213 | 0.120 |
Why?
|
| Cell Line | 7 | 2015 | 5114 | 0.120 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 488 | 0.120 |
Why?
|
| Monocytes | 2 | 2016 | 788 | 0.120 |
Why?
|
| Epitopes | 1 | 2016 | 685 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 1519 | 0.120 |
Why?
|
| Adult | 8 | 2023 | 77950 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2018 | 1226 | 0.110 |
Why?
|
| Cell Survival | 4 | 2019 | 3045 | 0.110 |
Why?
|
| Transplantation, Heterologous | 4 | 2007 | 1082 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2018 | 992 | 0.110 |
Why?
|
| HeLa Cells | 1 | 2016 | 1643 | 0.110 |
Why?
|
| Inflammation | 2 | 2022 | 2522 | 0.110 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2016 | 475 | 0.100 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 8865 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 1217 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1516 | 0.100 |
Why?
|
| Cell Proliferation | 4 | 2022 | 7226 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 987 | 0.100 |
Why?
|
| Exosomes | 1 | 2014 | 253 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 6942 | 0.100 |
Why?
|
| Immunologic Memory | 2 | 2023 | 374 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 1879 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2022 | 16273 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 1062 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 2173 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 3981 | 0.090 |
Why?
|
| CpG Islands | 1 | 2011 | 633 | 0.090 |
Why?
|
| DNA Repair | 2 | 2007 | 1872 | 0.090 |
Why?
|
| DNA Damage | 3 | 2019 | 1954 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2012 | 604 | 0.080 |
Why?
|
| Adolescent | 5 | 2022 | 31252 | 0.080 |
Why?
|
| Gene Amplification | 1 | 2011 | 731 | 0.080 |
Why?
|
| Cell Movement | 2 | 2018 | 2466 | 0.080 |
Why?
|
| Apoptosis | 4 | 2022 | 7591 | 0.080 |
Why?
|
| Receptor Cross-Talk | 1 | 2008 | 79 | 0.080 |
Why?
|
| E2F2 Transcription Factor | 1 | 2008 | 27 | 0.080 |
Why?
|
| Quality of Life | 1 | 2022 | 4532 | 0.080 |
Why?
|
| Astrocytes | 3 | 2022 | 368 | 0.080 |
Why?
|
| Cell Adhesion | 2 | 2010 | 1008 | 0.080 |
Why?
|
| Oxidoreductases | 1 | 2008 | 171 | 0.080 |
Why?
|
| Camptothecin | 2 | 2011 | 517 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 3639 | 0.080 |
Why?
|
| Oncogenes | 2 | 2008 | 673 | 0.080 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2007 | 12 | 0.080 |
Why?
|
| Genes, p16 | 1 | 2007 | 125 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 2314 | 0.070 |
Why?
|
| Cisplatin | 1 | 2014 | 2432 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3230 | 0.070 |
Why?
|
| Injections, Intralesional | 2 | 2018 | 164 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2022 | 5178 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2017 | 4078 | 0.070 |
Why?
|
| Integrin beta1 | 1 | 2006 | 126 | 0.070 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2006 | 57 | 0.070 |
Why?
|
| Everolimus | 1 | 2008 | 415 | 0.070 |
Why?
|
| Karyopherins | 1 | 2006 | 136 | 0.070 |
Why?
|
| Azacitidine | 1 | 2011 | 1149 | 0.070 |
Why?
|
| Cell Cycle | 2 | 2008 | 2084 | 0.060 |
Why?
|
| Estradiol | 1 | 2008 | 748 | 0.060 |
Why?
|
| Neuroglia | 1 | 2006 | 223 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2010 | 1048 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 7548 | 0.060 |
Why?
|
| Marriage | 1 | 2024 | 45 | 0.060 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2004 | 22 | 0.060 |
Why?
|
| Mice, Transgenic | 3 | 2007 | 4143 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2018 | 5270 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2022 | 32848 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 1 | 2008 | 701 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2008 | 1113 | 0.060 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 554 | 0.060 |
Why?
|
| Biopsy | 2 | 2023 | 3443 | 0.060 |
Why?
|
| Phenotype | 2 | 2011 | 6295 | 0.060 |
Why?
|
| Gene Expression | 2 | 2008 | 3570 | 0.060 |
Why?
|
| Mutation | 4 | 2023 | 15179 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 4654 | 0.050 |
Why?
|
| Mesencephalon | 1 | 2022 | 58 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2006 | 1764 | 0.050 |
Why?
|
| Chorioallantoic Membrane | 1 | 2022 | 25 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2007 | 986 | 0.050 |
Why?
|
| Melanoma | 1 | 2019 | 5317 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2007 | 1620 | 0.050 |
Why?
|
| alpha-Synuclein | 1 | 2022 | 118 | 0.050 |
Why?
|
| Chickens | 1 | 2022 | 523 | 0.050 |
Why?
|
| Models, Biological | 2 | 2010 | 3254 | 0.050 |
Why?
|
| Microglia | 1 | 2022 | 164 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 852 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2014 | 6150 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2015 | 1489 | 0.050 |
Why?
|
| Male | 9 | 2022 | 123000 | 0.050 |
Why?
|
| Liver | 2 | 2007 | 2961 | 0.050 |
Why?
|
| Proteins | 1 | 2008 | 1963 | 0.050 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 149 | 0.050 |
Why?
|
| Base Sequence | 3 | 2017 | 4917 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 541 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2018 | 9244 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 6207 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 3154 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 419 | 0.040 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 2018 | 36 | 0.040 |
Why?
|
| Female | 10 | 2020 | 141928 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 314 | 0.040 |
Why?
|
| Pediatrics | 2 | 2019 | 1141 | 0.040 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2018 | 55 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2007 | 2359 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 3251 | 0.040 |
Why?
|
| Survival Rate | 3 | 2019 | 12221 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2019 | 242 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2016 | 1248 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2018 | 392 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 1320 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2019 | 368 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 4892 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 677 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2019 | 1618 | 0.040 |
Why?
|
| Needles | 1 | 2017 | 107 | 0.040 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2016 | 39 | 0.040 |
Why?
|
| Genes, Synthetic | 1 | 2016 | 26 | 0.040 |
Why?
|
| Organisms, Genetically Modified | 1 | 2016 | 14 | 0.040 |
Why?
|
| Angiopoietin-2 | 1 | 2016 | 38 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 582 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2016 | 133 | 0.030 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2016 | 46 | 0.030 |
Why?
|
| Brain Stem | 1 | 2017 | 175 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2017 | 11965 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2016 | 252 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2018 | 842 | 0.030 |
Why?
|
| DNA Glycosylases | 1 | 2016 | 93 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2016 | 157 | 0.030 |
Why?
|
| Genes, Viral | 1 | 2016 | 202 | 0.030 |
Why?
|
| Unfolded Protein Response | 1 | 2016 | 115 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2016 | 126 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2016 | 172 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2018 | 4804 | 0.030 |
Why?
|
| Protein Binding | 2 | 2014 | 3438 | 0.030 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2014 | 37 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1681 | 0.030 |
Why?
|
| Extracellular Vesicles | 1 | 2017 | 135 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 237 | 0.030 |
Why?
|
| Necrosis | 1 | 2016 | 580 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1742 | 0.030 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2014 | 89 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2014 | 5637 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2014 | 289 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 193 | 0.030 |
Why?
|
| Nestin | 1 | 2013 | 42 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 5159 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2019 | 1529 | 0.030 |
Why?
|
| Tubulin | 1 | 2013 | 169 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 750 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2013 | 151 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 1301 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2014 | 181 | 0.030 |
Why?
|
| Rats | 1 | 2022 | 6086 | 0.030 |
Why?
|
| Prognosis | 2 | 2014 | 21713 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2013 | 222 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 360 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1763 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2013 | 275 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 671 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 663 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 1648 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 7702 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 1489 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2017 | 1549 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2016 | 2074 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2014 | 938 | 0.020 |
Why?
|
| Middle Aged | 4 | 2018 | 86204 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 483 | 0.020 |
Why?
|
| Mitochondria | 1 | 2016 | 1282 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 14289 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 5377 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2013 | 1152 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 1823 | 0.020 |
Why?
|
| Cell Communication | 1 | 2010 | 509 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 1533 | 0.020 |
Why?
|
| Young Adult | 2 | 2018 | 21445 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2007 | 260 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 2508 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2007 | 191 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2007 | 354 | 0.020 |
Why?
|
| Species Specificity | 1 | 2008 | 777 | 0.020 |
Why?
|
| Viruses | 1 | 2008 | 159 | 0.020 |
Why?
|
| Herpesviridae | 1 | 2006 | 42 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2007 | 611 | 0.020 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2006 | 75 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2007 | 652 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2008 | 482 | 0.020 |
Why?
|
| S Phase | 1 | 2006 | 281 | 0.020 |
Why?
|
| Purines | 1 | 2006 | 273 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2008 | 716 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 2216 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 9180 | 0.020 |
Why?
|
| Protein Transport | 1 | 2006 | 734 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 1493 | 0.020 |
Why?
|
| Luciferases | 1 | 2005 | 445 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 2004 | 264 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 6100 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 1390 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 4053 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2013 | 2819 | 0.010 |
Why?
|
| Neurons | 1 | 2013 | 2287 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2006 | 1313 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 11538 | 0.010 |
Why?
|
| Binding Sites | 1 | 2006 | 2171 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 2450 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 1399 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2007 | 1678 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 15862 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2007 | 1682 | 0.010 |
Why?
|
| Infant | 1 | 2016 | 13310 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 4233 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 6089 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 1547 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2004 | 1442 | 0.010 |
Why?
|
| DNA | 1 | 2007 | 2693 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 14889 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 13658 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 3203 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 37905 | 0.010 |
Why?
|
| Aged | 1 | 2014 | 70117 | 0.000 |
Why?
|